The European Commission wants to make it easier for patients to access cheaper generic medicines, a draft EU document seen by Reuters shows, in a move that could cut the revenues of big pharmaceutical firms.
If you are not happy with the results below please do another search
50 search results for:
Merck acquired Maryland-based OncoImmune and the Covid-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.
The U.S. Transportation Security Administration screened 1.047 million passengers on Nov. 22, the highest number since mid-March 2020.
AstraZeneca said on Monday the company’s Covid-19 vaccine could be as much as 90% effective, giving the world’s fight against the global pandemic a new weapon, cheaper to make, easier to distribute and faster to scale-up than rivals.
U.S. healthcare workers and others recommended for the nation’s first Covid-19 inoculations could start getting shots within a day or two of regulatory consent in December, a top official of the government’s vaccine development effort said.
Moderna will charge governments between $25 and $37 per dose of the company’s Covid-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).
The United States recorded the country’s 12th million Covid-19 case, even as millions of Americans were expected to travel for the upcoming Thanksgiving holiday, ignoring warnings from health officials about furthering the spread of the infectious disease.
The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.
AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.
Pfizer Inc. applied to U.S. health regulators for emergency use authorization (EUA) of the company’s Covid-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.